G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate sacituzumab govitecan on.
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
/PRNewswire/ CellFE Inc., a cell engineering platform company with a novel microfluidic technology for non-viral cell therapy manufacturing, announced today.
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib.